We are pleased to announce that a production clone with excellent productivity and quality for Strike Pharma’s complex bi-specific antibody was successfully generated with productivity of 5.8 g/L perfectly sufficient for commercial manufacturing. The clone shows very stable expression and excellent upstream process performance.

Strike Pharma’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology enables development of individualized immunotherapeutic treatments.

Read press release